201 related articles for article (PubMed ID: 31564852)
1. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():1431-1444. PubMed ID: 37465818
[TBL] [Abstract][Full Text] [Related]
3. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
4. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
6. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; Mahendran M; Hahn B
BMC Pulm Med; 2021 Jul; 21(1):253. PubMed ID: 34332555
[TBL] [Abstract][Full Text] [Related]
7. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
Moretz C; Cole AL; Mu G; Wu B; Guisinger A; Liu Y; Hahn B; Baylis L
Int J Chron Obstruct Pulmon Dis; 2020; 15():2207-2215. PubMed ID: 32982213
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Zheng J; Zhong N; Newlands A; Church A; Goh AH
Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
Driessen MT; Whalen J; Seewoodharry Buguth B; Vallejo-Aparicio LA; Naya IP; Asukai Y; Alcázar-Navarrete B; Miravitlles M; García-Río F; Risebrough NA
Respir Res; 2018 Nov; 19(1):224. PubMed ID: 30458866
[TBL] [Abstract][Full Text] [Related]
13. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
15. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
[TBL] [Abstract][Full Text] [Related]
16. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
17. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
[TBL] [Abstract][Full Text] [Related]
20. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
Sethi S; Clark B; Bengtson LGS; Buysman EK; Palli S; Sargent A; Shaikh A; Ferguson GT
Int J Chron Obstruct Pulmon Dis; 2023; 18():625-641. PubMed ID: 37155497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]